JP Morgan 43rd Annual Healthcare Conference

January 14, 2025

HAEMONETICS®

Important Information

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "forecasts," "foresees," "potential" and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for the operation of Haemonetics Corporation (the "Company"), including plans or objectives related to the Company's strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions; market position and expenditures; and the Company's Operational Excellence Program and portfolio rationalization initiatives; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company's share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

Non-GAAP Financial Measures

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results can be found in the Company's most recent Annual Report on Form 10-K under the headings "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" and in the Company's other periodic filings with the U.S. Securities and Exchange Commission (the "SEC"). The Company does not undertake to update these forward-looking statements.

This presentation contains non-GAAP financial measures as defined under applicable SEC rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with U.S. GAAP. We strongly encourage investors to review the Company's financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. To the extent available without unreasonable effort, we have provided reconciliations of these non-GAAP measures to their most comparable GAAP measure in Appendix A to this presentation, which is available on our website at www.haemonetics.com.

With the exception of fiscal 2025 revenue growth guidance, the Company does not provide a reconciliation of forward-looking non-GAAP measures because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts. Except as otherwise noted with respect to the Company's previously disclosed fiscal 2025 guidance, estimates of future financial performance represent the Company's long-term goals and are not intended as guidance. See "Safe Harbor for Forward-Looking Statements" above regarding forward-looking statements made in this presentation.

HAEMONETICS®

Haemonetics at a Glance

We develop innovative medical technology solutions to improve the quality, effectiveness, and efficiency of care

HAE
NYSE ticker

3600+
employees

90+
countries served

FY'24 Revenue





1) PL – Plasma, AP – Apheresis, WB – Whole Blood, BMT – Blood Management Technology, IVT – Interventional Technology.

HAEMONETICS®

FY’23 – FY’26 Transformational Growth

CORPORATE STRATEGY

Compete in winning segments and geographies

Achieve leading positions

Deliver superior operating performance

GOALS

GROWTH

- Revenue
- Profitability
- Cash Flow

DIVERSIFICATION

- Business Segments
- Customers
- Geographies
- Business Models

SUSTAINABILITY

- Economic
- People
- Societal
- Environmental

2022 Investor Day Long Range Plan Goals Support Robust Shareholder Value Creation

SUSTAINABLE GROWTH

HIGH SINGLE DIGIT
organic revenue CAGR

MID TEENS
CAGR in adjusted diluted EPS

INCREASING PROFITABILITY

HIGH TEENS
CAGR in adjusted operating income

HIGH TWENTIES
adjusted operating income margin in FY'26

CAPITAL ALLOCATION

$0.6B TO $0.7B
of cumulative FCF[1] FY'23 - FY'26

~$2B[2]
in capital capacity by the end of FY'26

1) Free cash flow. 2) Before acquisitions, divestitures and share buybacks, all of which are not included in the long range plan (LRP).

HAEMONETICS®

Value Drivers Support Transformational Growth

Strategic Portfolio Evolution

- Increasing growth and relevance in attractive markets, where Haemonetics is uniquely positioned to win

Multiple drivers of growth

Organic Growth

M&A

R&D

Operational Excellence

- Improving margins and leverage through our focus on quality, productivity, and agility

Reduce complexity and resilience against market disruptions and changing macro conditions.

Network optimization

Lean manufacturing

Vendor diversification

Process improvements

Resource Allocation

- Accelerating growth and value creation through capital allocation

Alignment of people, capital, and time to win in the most attractive markets

HAEMONETICS®

Increasing Our Exposure to Attractive, Growing Markets Through Purposeful Portfolio Evolution

Revenue
(organic revenue growth)



High-Growth Portfolio[1] (Core Products) includes:

	TAM	Market CAGR	FY24 Revenue	FY24 Organic Revenue Growth
Plasma	$0.8B	HSD	$570M	14%
Interventional Technologies	$4.1B	MSD	$174M	28%
Blood Management Technologies	$1.4B	MSD	$282M	11%

Durable Legacy Business includes:

	TAM	Market CAGR	FY24 Revenue	FY24 Organic Revenue Growth/ Decline
Apheresis	$0.6B	LSD	$211M	5%
Whole Blood[2]	$0.8B	LSD Decline	$72M	(9%)

Recent Divestiture

1) High-Growth Portfolio includes all product lines within Plasma and Hospital businesses. 2) Whole Blood divestiture was closed in January 2025.

Strong End-Market Growth Supported by Continued Need for Plasma-Derived Therapies

Plasma Market

$0.8B TAM	HSD CAGR

US Plasma collections[1]



Market Trends

Short-term:

- Emphasis on Cost Per Liter (CPL) drives collectors' focus on maximizing yield and efficiency.
- Same-center collections at ~80% of historical capacity[4] provide room for growth within existing centers.
- Strong demand for Persona and Express Plus creates the opportunity for global market share gains.

Long-term:

- Lack of alternatives to treat immunodeficiency and autoimmune conditions is expected to drive 6-8% CAGR in Ig volume from 2021 to 2030[2]
- Plasma fractionation capacity is projected to increase at ~7% CAGR from 2022 to 2032[3]
- > 10,000 in registered clinical trials evaluating IVIG as a treatment modality[5]
- Rapid growth of subcutaneous Ig, often requiring higher dosage to match the efficacy IVIG.

1) PPTA data. Collections per center are calculated as total collections in any given year divided by the total number of plasma centers. 2) Privately conducted third party research as of August 2024. 3) The Global Plasma Fractionation Landscape: Plasma Fractionation Capacities and Throughputs by Country & Company in 2023 and Forecast to 2032, Marketing Research Bureau; February 2024 4) Historical capacity is calculated as 2023 collections per center divided by average collections per plasma center between 2014 and 2019. 5) Clinicaltrials.gov search for Immunoglobulin.

HAEMONETICS®

Accelerating Revenue Growth And Margin Expansion Through Value-Adding Technology* in Plasma

Market-leading position

- Global collections **market share leader**
- **Nearly 100%** recurring revenue (disposables and software)

Unrivaled plasma center capabilities

- **~9 -12%** more plasma on average with Persona[1,2]
- **~16-minute** shorter plasma center visit[1,2,3]
- **~98%** elimination of documentation errors
- **~20%** shorter procedure expected with NexSys PCS updates[1,2,4]

Continuous growth innovation

- Innovation focused on **yield, productivity, safety**, and **donor experience**
- Continue to **redefine the basis for competition**
- Global market expansion

The only provider of the fully integrated plasma collection solutions focused on reducing
Cost Per Liter (CPL)



*Not all products and features are available in all markets. 1) Representative in-market results, surveys. 2) Based on baseline device, software configuration and donor population. 3) Excludes Persona® Technology. 4) On average using Express® Plus Technology.

HAEMONETICS®

Extending Our Reach and Relevance With High-Growth, High-Margin Products* in Hospitals

Blood Management Technologies

Hemostasis Management

Transfusion Management

Cell Salvage

Hemostasis Management	Transfusion Management	Cell Salvage
$0.8B TAM[3] MSD CAGR	$0.4B TAM[3] MSD CAGR	$0.2B TAM[3] LSD CAGR

- Sales and clinical capabilities support market share gains and increase utilization
- Introduction of the new assays on the TEG® 6s platform accelerates adoption
- Opportunity to expand into new markets

Interventional Technologies

Recent Acquisitions

Vascular Closure

Esophageal Protection[1]

Sensor Guided Technologies[2]

Vascular Closure	Esophageal Protection[1]	Sensor Guided Technologies[2]
$2.7B TAM[3,4] HSD CAGR	$0.3B TAM[3] MSD CAGR	$1.1B TAM[3] MSD CAGR

- Proven commercial strategy drives swift account penetration and market share expansion
- Highly synergistic portfolio enables cross-portfolio pull-through
- Significant opportunity to expand portfolio with additional R&D and M&A

*Not all products and features are available in all markets. 1) EnsoETM proactive esophageal protection technology acquired with Attune Medical in April 2024. Esophageal protection indication is limited to US. 2) Sensor guided technologies acquired with OpsSens Inc. in December 2023. 3) Total Addressable Market in calendar year 2024. 4) TAM for both Electrophysiology ($1.0B growing in Low Teens) and Coronary & Peripheral ($1.7B growing LSD).

Driving Adoption in the Viscoelastic Testing Market with TEG® 6s



Clinical Segment	% of TAM
Interventional Cardiology	~30%
CV Surgery	~40%
Trauma	~15%
Others[2]	~15%
Total	**100%**

Growth Strategy:

- **Drive penetration into core clinical segments**
- **Increase utilization through training and education**
- **Expand sales and clinical teams**
- **Unique go-to-market strategies and market-specific product innovation**
- **Expand clinical segments**
- **Expand product portfolio**

1) Data sources (updated procedure numbers) from iData, DRG/Clarivate, MedTech Insight, internal Company estimates. Addressable market = potential procedures annually in Top 7 geographies X average test utilization X average selling price; does not include other geographies and capital sales 2) Liver Transplant and External Labs

HAEMONETICS®

Establishing Standard of Care with Vascular Closure in Electrophysiology in the US

US EP Procedures[1]

- **#1 Market Leader in Electrophysiology (EP)**
- **More than 80%** of Top 600 accounts are regular users of Vascade MVP® and/or Vascade MVP® XL
- Emerging trends in the treatment of **atrial fibrillation** are expected to **accelerate growth from Low Teens to Mid Teens** in the mid-term



2024 US EP Procedures[1,5]



Procedures	Afib	VT	SVT/FL	LAAC
Access sites[2,3]	3.1	3.2	3.2	1.5
3yrs CAGR[4]	Low Teens	Low Single Digit	Low Single Digit	Low Teens

1) Total US electrophysiology procedures data was derived from DRG/Clarivate. Market share percentages were calculated based on privately conducted 3rd party primary market research and internal market models. MC stands for Manual Compression. Other Vascular Closure Devices include Perclose and Mynx. 2) Average number of access sites created during the procedure requiring closure 3) Independent third-party primary market research (survey) from Q3 of CY 2024 of ~60 US EP doctors 4) Procedure growth from 2021-2024. 5) Afib – atrial fibrillation ablation, VT – Ventricular Tachycardia ablation, SVT – Supra Ventricular Tachycardia, FL – Atrial Flutter

HAEMONETICS®

Accelerating Growth, Expanding Product Portfolio, and Market Leadership Through Innovation

Strategic investments in R&D



>$1B allocated to M&A since 2020:

attunemedical

OpSens

CARDIVA MEDICAL, INC.

TEG® 6s
Hemostasis Analyzer System Technology (IP)

M&A and R&D STRATEGY

- ✓ Aligned with the corporate strategy of winning markets, leading positions, and attractive financial returns
- ✓ M&A pipeline includes late-stage investment portfolio
- ✓ Near-term focus on strategic fit and synergies

HAEMONETICS®

On Track to Create Value and Accelerate Growth

	LRP Goals	FY'23	FY'24
Organic Revenue Growth[1]	High Single Digit (FY'22 – FY'26 CAGR)	21%	12%
Adjusted Operating Margin[2]	High Twenties (in FY'26)	18.7%	21.1% +240bps vs. FY'23
Adjusted EPS Growth[3]	Mid Teens (FY'22 – FY'26 CAGR)	~17%	~31%
Free Cash Flow[4]	$600M - $700M (in cumulative FCF FY'23 – FY'26)	$164M	$117M

- ✓ Revenue and adjusted EPS growth ahead of plan
- ✓ Adjusted operating margin exceeded historical high of 22% beginning in Q2 FY'25[2]
- ✓ Strong FCF enables to pull-forward organic investments and funds additional growth

1) Organic revenue growth excludes the impact of currency fluctuation, acquisitions and strategic exits of product lines. 2) Adjusted operating margin equals (i) adjusted operating income divided by (ii) revenue determined in accordance with GAAP. 3) Adjusted earnings per diluted share excludes restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, asset impairments and write downs, amortization of fair value inventory step-up, accelerated device depreciation and related costs, costs related to compliance with the European Union MDR and IVDR, integration and transaction costs, net gains on the repurchase of convertible notes, gains on sales of property, plant and equipment, certain tax settlements and unusual or infrequent and material litigation-related charges. Adjusted earnings per diluted share also excludes the tax impact of these items. 4) Free Cash Flow is calculated as Cash From Operations minus capital expenditures, net of proceeds from sale of property, plant and equipment.

HAEMONETICS®

Disciplined Capital Allocation Strategy Supports Continuous Value-Creation Opportunities

CAPITAL CAPACITY

~2B[1]

ORGANIC INVESTMENTS[2]	STRATEGIC M&A	SHARE BUYBACKS AND DEBT REPAYMENT
High impact and high ROI drivers	High-growth leading products	Return capital to stakeholders

1) Before acquisitions, divestitures and share buybacks, all of which are not included in the long range plan (LRP). 2) Incremental organic investments not funded in long range plan.

HAEMONETICS®

Evolutionary steps to achieve **Revolutionary results**

Appendix A

Reconciliation of Reported Revenue Growth to Organic Revenue Growth

(In thousands)	Six Months Ended 9/28/2024	Six Months Ended 9/30/2023	Reported Growth	Currency Impact[1]	Acquisitions[2]	Organic Growth
	(unaudited)					
Revenues by business unit						
Plasma	**$ 274,471**	**$ 282,415**	**(2.8) %**	**- %**	**- %**	**(2.8) %**
Apheresis	103,426	104,139	(0.7) %	(2.0) %	- %	1.3 %
Whole Blood	31,347	34,723	(9.7) %	(0.1) %	- %	(9.6) %
Blood Center	**134,773**	**138,862**	**(2.9) %**	**(1.4) %**	**- %**	**(1.5) %**
Interventional Technologies	124,967	76,161	64.1 %	(0.3) %	44.9 %	19.5 %
Blood Management Technologies	147,472	132,077	11.7 %	(0.2) %	- %	11.9 %
Hospital	**272,439**	**208,238**	**30.8 %**	**(0.3) %**	**16.4 %**	**14.7 %**
Total net revenues	**$ 681,683**	**$ 629,515**	**8.3 %**	**(0.4) %**	**5.4 %**	**3.3 %**

1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. 2) Reflects the impact in Hospital of the Sensor Guided Technologies product line acquired as part of the OpSens Inc. transaction in December 2023 and the Esophageal Protection product line acquired as part of the Attune Medical transaction in April 2024.

HAEMONETICS®

Reconciliation of Reported Revenue Growth to Organic Revenue Growth (continued)

	Year Ended					
	3/30/2024	4/1/2023	Reported Growth	Currency Impact[1]	Acquisitions[2]	Organic Growth
(In thousands)	*(unaudited)*					
Revenues by business unit						
Plasma	**$ 569,535**	**$ 499,916**	**13.9 %**	**0.1 %**	**- %**	**13.8 %**
Apheresis	211,173	207,618	1.7 %	(3.0) %	- %	4.7 %
Whole Blood	72,058	79,416	(9.3) %	(0.6) %	- %	(8.7) %
Blood Center	**283,231**	**287,034**	**(1.3) %**	**(2.3) %**	**- %**	**1.0 %**
Interventional Technologies	174,285	126,717	37.5 %	(0.2) %	9.3 %	28.4 %
Blood Management Technologies	282,004	254,993	10.6 %	(0.6) %	- %	11.2 %
Hospital	**456,289**	**381,710**	**19.5 %**	**(0.5) %**	**3.1 %**	**16.9 %**
Total net revenues	**$ 1,309,055**	**$ 1,168,660**	**12.0 %**	**(0.7) %**	**1.0 %**	**11.7 %**

1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. 2) Reflects the impact in Hospital of the Sensor Guided Technologies product line acquired as part of the OpSens Inc. transaction in December 2023.

HAEMONETICS®

Reconciliation of Reported Revenue Growth to Organic Revenue Growth (continued)

	Year Ended						
	4/2/2022	4/3/2021	3/28/2020	3/30/2019	3/31/2018	4/1/2017	4/2/2016
				(unaudited)			
Revenue Growth Rates							
Reported Growth	**14.1 %**	**(11.9) %**	**2.2 %**	**7.0 %**	**2.0 %**	**(2.5) %**	**(0.2) %**
Less: Currency Impact	0.7 %	1.0 %	(0.6) %	0.0 %	0.9 %	(1.3) %	(3.1) %
Constant Currency Growth	13.4 %	(12.9) %	2.8 %	7.0 %	1.1 %	(1.2) %	2.9 %
Less: Acquisitions and Divestitures[1]	8.7 %	(0.2) %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Less: Other Strategic Exits[2]	(0.9) %	(0.8) %	(2.4) %	0.0 %	(0.7) %	0.0 %	0.0 %
Less: 53rd Week[3]	(1.5) %	0.6 %	0.0 %	0.0 %	0.0 %	(2.0) %	1.7 %
Less: End of Life[4]	0.0 %	0.0 %	(1.1) %	0.0 %	0.0 %	0.0 %	0.0 %
Organic Growth	**7.1 %**	**(12.5) %**	**6.3 %**	**7.0 %**	**1.8 %**	**0.8 %**	**1.2 %**

1) Acquisition and divestitures including the acquisition of Vascular Closure from Cardiva Medical Inc. in Hospital, the divestiture of the Company's U.S. Blood Donor Management Software Solutions assets in Blood Center and the divestiture of InLog Holdings France SAS in Blood Center and Hospital 2) Certain strategic exits within liquid solutions business and SEBRA divestiture in Plasma 3) The impact of the 53rd week. 4) OrthoPAT product end of life in Hospital

HAEMONETICS®

Reconciliation of Cash Provided by Operating Activities (GAAP) to Free Cash Flow

(In thousands)	Six Months Ended 9/28/2024 *(unaudited)*		Year Ended 3/30/2024 *(unaudited)*	
Free Cash Flow Reconciliation:				
Cash provided by operating activities	$	21,402	$	181,751
Capital expenditures		(15,089)		(37,515)
Additions to Haemonetics equipment		(6,754)		(28,781)
Proceeds from sale of property, plant and equipment		20,551		1,810
Free cash flow	**$**	**20,110**	**$**	**117,265**

HAEMONETICS®

Reconciliation of GAAP Operating Income to Adjusted Operating Income

(In thousands)	Six Months Ended 9/28/2024 (unaudited)		Year Ended 3/30/2024 (unaudited)	
GAAP operating income	**$**	**91,453**	**$**	**164,883**
Amortization of acquired intangible assets		24,735		32,031
Amortization of fair value inventory step-up		8,978		3,347
Integration and transaction costs		13,205		11,249
Restructuring costs		9,414		14,089
Restructuring related costs		4,089		9,499
Digital transformation costs		11,203		15,667
Write downs of certain in-process intangible assets and PCS2 related charges		-		5,095
MDR and IVDR costs[1]		2,117		5,588
Litigation-related charges		1,075		6,670
Impairment of intangible assets		2,391		10,419
Gains on sales of property, plant and equipment		(14,134)		-
Gain on divestiture		-		(2,000)
Adjusted operating income	**$**	**154,526**	**$**	**276,537**

[1] Refers to European Union Medical Device Regulation ("MDR") and In Vitro Diagnostic Regulation ("IVDR") related costs.

1) Refers to European Union Medical Device Regulation ("MDR") and In Vitro Diagnostic Regulation ("IVDR") related costs.

Reconciliation of GAAP Earnings Per Share to Adjusted Earnings Per Share

	Six Months Ended		Year Ended	
	9/28/2024	9/30/2023	3/30/2024	4/1/2023
(In thousands except per share data)	*(unaudited)*		*(unaudited)*	
GAAP net income	**$ 72,204**	**$ 65,950**	**$ 117,558**	**$ 115,401**
Amortization of acquired intangible assets	24,735	14,695	32,031	32,640
Amortization of fair value inventory step-up	8,978	-	3,347	-
Integration and transaction costs	13,205	2,899	11,249	(411)
Restructuring costs	9,414	75	14,089	657
Restructuring related costs	4,089	4,151	9,499	10,892
Digital transformation costs	11,203	7,297	15,667	4,536
Write downs of certain in-process intangible assets and PCS2 related charges	-	411	5,095	(616)
MDR and IVDR costs[1]	2,117	3,154	5,588	9,854
Litigation-related charges	1,075	6,507	6,670	5,230
Impairment of intangible assets	2,391	10,419	10,419	-
Gains on sales of property, plant and equipment	(14,134)	-	-	-
Gain on divestiture and sale of assets	-	-	(2,000)	(382)
Gain on repurchase of convertible notes, net	(12,600)	-	-	-
Tax impact associated with adjustments	(13,031)	(11,218)	(25,579)	(22,098)
Adjusted net income	**$ 109,646**	**$ 104,340**	**$ 203,633**	**$ 155,703**
GAAP net income per common share	**$ 1.40**	**$ 1.28**	**$ 2.29**	**$ 2.24**
Adjusted items after tax per common share assuming dilution	0.73	0.75	1.67	0.79
Adjusted net income per common share assuming dilution	**$ 2.13**	**$ 2.03**	**$ 3.96**	**$ 3.03**

[1] Refers to European Union MDR and IVDR related costs.

1) Refers to European Union MDR and IVDR related costs.

HAEMONETICS®